{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T13:07:56Z","timestamp":1770901676160,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T00:00:00Z","timestamp":1613520000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cerebral radiation injury, including subacute radiation reactions and later stage radiation necrosis, is a severe side effect of brain tumor radiotherapy. A protocol of four infusions of the monoclonal antibody bevacizumab has been shown to be a highly effective treatment. However, bevacizumab is costly and can cause severe complications including thrombosis, bleeding and gastrointestinal perforations.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We performed a retrospective analysis of patients treated in our clinic for cerebral radiation injury who received only a singular treatment with bevacizumab. Single-shot was defined as a singular administration of bevacizumab without a second administration during an interval of at least 6 weeks.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We identified 11 patients who had received a singular administration of bevacizumab to treat cerebral radiation injury. Prior radiation had been administered to treat gliomas (ten patients) or breast cancer brain metastases (one patient). 9 of 10 patients with available MRIs showed a marked reduction of edema at first follow-up. Discontinuation of Dexamethasone was possible in 6 patients and a significant dose reduction could be achieved in all other patients. One patient developed pulmonary artery embolism 2 months after bevacizumab administration. The median time to treatment failure of any cause was 3 months.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Single-shot bevacizumab therefore has meaningful activity in cerebral radiation injury, but durable control is rarely achieved. In patients where a complete protocol of four infusions with bevacizumab is not feasible due to medical contraindications or lack of reimbursement, single-shot bevacizumab treatment may be considered.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12883-021-02103-0","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T07:42:38Z","timestamp":1613806958000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Single-shot bevacizumab for cerebral radiation injury"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8469-8204","authenticated-orcid":false,"given":"Martin","family":"Voss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8640-6858","authenticated-orcid":false,"given":"Katharina J.","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanouil","family":"Fokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7055-543X","authenticated-orcid":false,"given":"Marie-Th\u00e9r\u00e8se","family":"Forster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim P.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1402-6290","authenticated-orcid":false,"given":"Michael W.","family":"Ronellenfitsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,17]]},"reference":[{"key":"2103_CR1","doi-asserted-by":"publisher","first-page":"e8293","DOI":"10.1097\/MD.0000000000008293","volume":"96 43","author":"K Fetcko","year":"2017","unstructured":"Fetcko K, Lukas RV, Watson GA, Zhang L, Dey M. Survival and complications of stereotactic radiosurgery: A systematic review of stereotactic radiosurgery for newly diagnosed and recurrent high-grade gliomas. Med (Baltim). 2017;96 43:e8293. doi:https:\/\/doi.org\/10.1097\/MD.0000000000008293.","journal-title":"Med (Baltim)"},{"key":"2103_CR2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s11060-017-2375-2","volume":"134 3","author":"BM Ellingson","year":"2017","unstructured":"Ellingson BM, Chung C, Pope WB, Boxerman JL, Kaufmann TJ. Pseudoprogression, radionecrosis, inflammation or true tumor progression? challenges associated with glioblastoma response assessment in an evolving therapeutic landscape. J Neurooncol. 2017;134 3:495\u2013504. doi:https:\/\/doi.org\/10.1007\/s11060-017-2375-2.","journal-title":"J Neurooncol"},{"key":"2103_CR3","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3349\/ymj.2018.59.2.194","volume":"59 2","author":"J Lee","year":"2018","unstructured":"Lee J, Ahn SS, Chang JH, Suh CO. Hypofractionated Re-irradiation after Maximal Surgical Resection for Recurrent Glioblastoma: Therapeutic Adequacy and Its Prognosticators of Survival. Yonsei Med J. 2018;59 2:194\u2013201. doi:https:\/\/doi.org\/10.3349\/ymj.2018.59.2.194.","journal-title":"Yonsei Med J"},{"key":"2103_CR4","doi-asserted-by":"publisher","first-page":"3342","DOI":"10.1158\/1078-0432.CCR-03-0426","volume":"10 10","author":"RA Nordal","year":"2004","unstructured":"Nordal RA, Nagy A, Pintilie M, Wong CS. Hypoxia and hypoxia-inducible factor-1 target genes in central nervous system radiation injury: a role for vascular endothelial growth factor. Clin Cancer Res. 2004;10 10:3342\u201353. doi:https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0426.","journal-title":"Clin Cancer Res"},{"key":"2103_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1308573","volume":"370 8","author":"MR Gilbert","year":"2014","unstructured":"Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370 8:699\u2013708. doi:https:\/\/doi.org\/10.1056\/NEJMoa1308573.","journal-title":"N Engl J Med"},{"key":"2103_CR6","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1200\/JCO.2015.63.4691","volume":"34 14","author":"U Herrlinger","year":"2016","unstructured":"Herrlinger U, Schafer N, Steinbach JP, Weyerbrock A, Hau P, Goldbrunner R, et al. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial. J Clin Oncol. 2016;34 14:1611\u20139. https:\/\/doi.org\/10.1200\/JCO.2015.63.4691.","journal-title":"J Clin Oncol"},{"key":"2103_CR7","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1308345","volume":"370 8","author":"OL Chinot","year":"2014","unstructured":"Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370 8:709\u201322. doi:https:\/\/doi.org\/10.1056\/NEJMoa1308345.","journal-title":"N Engl J Med"},{"key":"2103_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/neuonc\/now091","volume":"18 10","author":"W Wick","year":"2016","unstructured":"Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, et al. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy\/temozolomide for newly diagnosed glioblastoma. Neuro Oncol. 2016;18 10:1434\u201341. doi:https:\/\/doi.org\/10.1093\/neuonc\/now091.","journal-title":"Neuro Oncol"},{"key":"2103_CR9","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1016\/j.ijrobp.2009.12.061","volume":"79 5","author":"VA Levin","year":"2011","unstructured":"Levin VA, Bidaut L, Hou P, Kumar AJ, Wefel JS, Bekele BN, et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys. 2011;79 5:1487\u201395. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2009.12.061.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR10","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1001\/jama.2008.656","volume":"300 19","author":"SR Nalluri","year":"2008","unstructured":"Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300 19:2277\u201385. doi:https:\/\/doi.org\/10.1001\/jama.2008.656.","journal-title":"JAMA"},{"key":"2103_CR11","doi-asserted-by":"publisher","first-page":"14698","DOI":"10.1038\/srep14698","volume":"5","author":"X Li","year":"2015","unstructured":"Li X, Huang R, Xu Z. Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis. Sci Rep. 2015;5:14698. doi:https:\/\/doi.org\/10.1038\/srep14698.","journal-title":"Sci Rep"},{"key":"2103_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.bulcan.2018.07.010","volume":"105 12","author":"L Sirven-Villaros","year":"2018","unstructured":"Sirven-Villaros L, Bourg V, Suissa L, Mondot L, Almairac F, Fontaine D, et al. Bevacizumab: Is the lower the better for glioblastoma patients in progression? Bull Cancer. 2018;105 12:1135\u201346. doi:https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.010.","journal-title":"Bull Cancer"},{"key":"2103_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11060-017-2553-2","volume":"135 1","author":"A Ajlan","year":"2017","unstructured":"Ajlan A, Thomas P, Albakr A, Nagpal S, Recht L. Optimizing bevacizumab dosing in glioblastoma: less is more. J Neurooncol. 2017;135 1:99\u2013105. doi:https:\/\/doi.org\/10.1007\/s11060-017-2553-2.","journal-title":"J Neurooncol"},{"issue":"2","key":"2103_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11060-011-0748-5","volume":"107","author":"V Lorgis","year":"2012","unstructured":"Lorgis V, Maura G, Coppa G, Hassani K, Taillandier L, Chauffert B, et al. Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. J Neurooncol. 2012;107(2):351\u20138. doi:https:\/\/doi.org\/10.1007\/s11060-011-0748-5.","journal-title":"J Neurooncol"},{"key":"2103_CR15","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","volume":"393 10172","author":"U Herrlinger","year":"2019","unstructured":"Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, et al. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393 10172:678\u201388. doi:https:\/\/doi.org\/10.1016\/S0140-6736(18)31791-4.","journal-title":"Lancet"},{"issue":"1","key":"2103_CR16","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3171\/2014.9.PEDS14198","volume":"15","author":"SR Dashti","year":"2015","unstructured":"Dashti SR, Spalding A, Kadner RJ, Yao T, Kumar A, Sun DA, et al. Targeted intraarterial anti-VEGF therapy for medically refractory radiation necrosis in the brain. J Neurosurg Pediatr. 2015;15(1):20\u20135. doi:https:\/\/doi.org\/10.3171\/2014.9.PEDS14198.","journal-title":"J Neurosurg Pediatr"},{"key":"2103_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11060-015-1846-6","volume":"124 3","author":"S Joshi","year":"2015","unstructured":"Joshi S, Ellis JA, Ornstein E, Bruce JN. Intraarterial drug delivery for glioblastoma mutiforme: Will the phoenix rise again? J Neurooncol. 2015;124 3:333\u201343. doi:https:\/\/doi.org\/10.1007\/s11060-015-1846-6.","journal-title":"J Neurooncol"},{"key":"2103_CR18","doi-asserted-by":"publisher","first-page":"48842","DOI":"10.18632\/oncotarget.7768","volume":"7 30","author":"H Zhuang","year":"2016","unstructured":"Zhuang H, Yuan X, Chang JY, Song Y, Wang J, Yuan Z, et al. Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. Oncotarget. 2016;7 30:48842\u20139. doi:https:\/\/doi.org\/10.18632\/oncotarget.7768.","journal-title":"Oncotarget"},{"key":"2103_CR19","doi-asserted-by":"publisher","first-page":"8447","DOI":"10.2147\/OTT.S223258","volume":"12","author":"H Zhuang","year":"2019","unstructured":"Zhuang H, Zhuang H, Shi S, Wang Y. Ultra-Low-Dose Bevacizumab For Cerebral Radiation Necrosis: A Prospective Phase II Clinical Study. Onco Targets Ther. 2019;12:8447\u201353. doi:https:\/\/doi.org\/10.2147\/OTT.S223258.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2103_CR20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/15384047.2016.1276127","volume":"18","author":"X Meng","year":"2017","unstructured":"Meng X, Zhao R, Wu S, Shen G, Ding L, Sun B, et al. Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report. Cancer Biol Ther. 2017;18(1):63\u20136. doi:https:\/\/doi.org\/10.1080\/15384047.2016.1276127.","journal-title":"Cancer Biol Ther"},{"key":"2103_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.ijrobp.2017.06.2466","volume":"99 4","author":"J Clarke","year":"2017","unstructured":"Clarke J, Neil E, Terziev R, Gutin P, Barani I, Kaley T, et al. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma. Int J Radiat Oncol Biol Phys. 2017;99 4:797\u2013804. doi:https:\/\/doi.org\/10.1016\/j.ijrobp.2017.06.2466.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2103_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1080\/15384047.2018.1433499","volume":"19 6","author":"M Xiangying","year":"2018","unstructured":"Xiangying M, Rugang Z, Lijuan D, Yaowei Z, Bing S, Junliang W, et al. Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery: A case report. Cancer Biol Ther. 2018;19 6:461\u20134. doi:https:\/\/doi.org\/10.1080\/15384047.2018.1433499.","journal-title":"Cancer Biol Ther"},{"issue":"2","key":"2103_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s11060-014-1488-0","volume":"119","author":"Y Wang","year":"2014","unstructured":"Wang Y, Wang E, Pan L, Dai J, Zhang N, Wang X, et al. A new strategy of CyberKnife treatment system based radiosurgery followed by early use of adjuvant bevacizumab treatment for brain metastasis with extensive cerebral edema. J Neurooncol. 2014;119(2):369\u201376. doi:https:\/\/doi.org\/10.1007\/s11060-014-1488-0.","journal-title":"J Neurooncol"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12883-021-02103-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12883-021-02103-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,4]],"date-time":"2021-05-04T14:06:06Z","timestamp":1620137166000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/s12883-021-02103-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2103"],"URL":"https:\/\/doi.org\/10.1186\/s12883-021-02103-0","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,17]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Open Access funding note to be added to fulfill the contractual requirement of the Germany fully OA\/Sweden fully OA agreement. The article has been updated.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written consent by the individual patient for this retrospective data collection was waived by the ethics committee of the University Hospital Frankfurt; Goethe University which also approved the access to the patients\u2019 data (IRB decision # 4\/09, project SNO_01\u201308).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No individual person\u2019s data is included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"J.P.S. has received honoraria for lectures or advisory board participation, consulting or travel grants from Abbvie, Roche, Boehringer, Bristol-Myers Squibb, Medac, Mundipharma and UCB. M.W.R. has received a grant from UCB. The other authors report no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}